arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Keros Therapeutics, Inc.

KROS

$11.13 ▲ +0.47 (+4.41%) at close

8 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Keros Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $414.3M

Dividend Yield —

Revenue Growth 6775.0% ↗

Op. Margin 27.7%

ROIC 21.1% ↗

FCF / Share $2.85 ↗

Trailing P/E 4.8x

Price / Book 0.7x

FCF Yield 25.6%

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$244.06M

↑ +6775.0% —

Net Income Profit after all expenses

$87.01M

↑ +146.4% —

Operating Margin Operating profit as % of sales

27.7%

↑ +109.9% 84th

FCF / Share Free cash flow per share

$2.85

↑ +165.5% —

trending_up

Bullish Indicators

Operating Margin (%)Operating Margin (%) is in the top quartile
Profit Margin (%)Profit Margin (%) is in the top quartile
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Profitability

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	6775.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+84587%)	2251.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+28037%)	—	N/M	—	N/M	—	—
EPS Growth YoY (%)	N/M	3.8% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-25.3% Weak → Weak Stable Year-over-year change in earnings per share Optimal: > 10%	-64.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	14.0% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	N/M	-22.5% Weak ↑ Weak Improving Year-over-year change in net income	-46.2% Weak ↑ Weak Improving Year-over-year change in net income	-78.2% Weak ↑ Weak Improving Year-over-year change in net income	-29.5% Weak Weak Year-over-year change in net income	-267.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	-0.9% Weak ↑ Weak Improving Year-over-year change in free cash flow	-52.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	-4.3% Weak Weak Year-over-year change in free cash flow	-12.9% Weak Weak Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	—	-43.9% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	-18.7% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	27.7% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+85%)	—	—	—	-280.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1970%)	—	-105.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-804%)	—
Effective Tax Rate (%) (%)	5.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-3.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	35.7% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+197%)	—	—	—	-292.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2535%)	—	-123.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1128%)	—
FCF Margin (%) (%)	43.4% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	-314.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-162.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.22x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.32x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	21.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-36.9% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-51.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	54.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	20.0% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-34.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-45.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-96.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	28.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+91%)	-32.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-319%)	-46.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-407%)	-37.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-352%)	-24.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-261%)	-17.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-216%)	63.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+323%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Interest Coverage (x)	—	—	—	-114790.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-14093.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	-7776.17x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-287.42M	$-559.93M	$-331.15M	$-279.05M	$-230.04M	$-265.88M	$-7.02M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$6.56	$0.09	$0.01	$0.00	$0.86	$0.00	—	—
Basic EPS, GAAP (USD)	$2.34	$-5.00	$-5.20	$-4.15	$-2.52	$-2.93	—	—
Free Cash Flow per Share (USD)	$2.85	$-4.35	$-4.31	$-2.82	$-2.71	$-2.40	—	—
Book Value per Share (USD)	$15.51	$14.09	$10.43	$10.07	$10.14	$11.28	$-8.00	—
Tangible Book Value per Share (USD)	$15.51	$14.09	$10.43	$10.07	$10.14	$11.28	$-8.00	—
Basic Weighted Avg Shares (shares)	37.22M	37.44M	29.45M	25.24M	23.33M	15.51M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$295.02M	$561.44M	$322.92M	$269.22M	$239.59M	$260.54M	$4.44M	—
Total Equity (USD)	$303.13M	$571.55M	$332.21M	$277.42M	$243.17M	$261.72M	$-19.45M	$-7.18M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$244.06M	$3.55M	$151.00K	$0.00	$20.10M	$0.00	$10.00M	—
Depreciation Expense (USD)	$1.51M	$1.23M	$815.00K	$674.00K	$378.00K	$278.00K	$208.00K	—
Net Income, GAAP (USD)	$87.01M	$-187.35M	$-152.99M	$-104.68M	$-58.74M	$-45.36M	$-12.34M	—
Operating Cash Flow (USD)	$107.50M	$-160.87M	$-124.51M	$-70.06M	$-62.15M	$-36.89M	$-16.00M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Keros Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KROS with peers